Advertisement: mid banner EY
Advertisement: Lynch Wood Park
RealVNC mid banner careers
Advertisement: KISS
Advertisement: Mobas mid banner
Barr Ellison Solicitors – commercial property
Advertisement: Cambridge Network
Advertisement: CPL mid banner
Advertisement: Bradfield Centre mid
RealVNC mid-banner general
ARM Innovation Hub
Advertisement: Bridge Fibre mid
6 August, 2018 - 15:56 By Kate Sweeney

Avacta hits right note for Bach BioSciences

Avacta laboratory

Avacta Group in Cambridge, which develops Affimer® biotherapeutics and reagents, has struck a key deal with a US partner. 

Avacta has agreed a co-development partnership with Bach BioSciences, which is commercialising the research of William Bachovchin, Professor of Developmental, Chemical and Molecular Biology at Tufts University School of Medicine, Boston.
 
The collaboration will develop a new class of Affimer drug conjugate therapies with a novel mode of action that combines Avacta’s Affimer technology with drug conjugates developed at Tufts.

In a ground-breaking co-invention with Tufts, the company has devised a new class of drug conjugate. This selectively releases a potent drug in the tumour microenvironment without requiring cellular internalisation of the conjugate as is otherwise the case with traditional antibody-drug conjugates. Avacta and Tufts have jointly filed for broad patent protection for this inventive concept. 

The patent covers Affimers and a wide range of other binders, against oncology, viral and inflammatory targets that are not internalised rapidly enough to be useful in traditional antibody-drug conjugates. 

Newsletter Subscription

Stay informed of the latest news and features